At least  months from allogeneic stem cell transplantation and off immunosuppression and no evidence of graft versus host disease (GVHD)
Has undergone prior allogeneic hematopoietic stem cell transplantation within the last  years. (Note: Participants who have had a stem cell transplant > years ago are eligible as long as there are no symptoms of graft-versus-host disease [GVHD].)
Has undergone solid organ transplant at any time, or prior allogeneic hematopoietic stem cell transplantation within the last  years. (Participants who have had an allogeneic hematopoietic transplant > years ago are eligible as long as there are no symptoms of Graft Versus Host Disease [GVHD].)
Patients who have undergone stem cell transplantation (SCT), autologous or allogeneic, are eligible provided that they are >=  weeks from stem cell infusion, have no active graft versus host disease (GVHD), are off immune suppression for at least  weeks, and do not have a history of veno-occlusive disease (VOD)
Prior allogeneic stem cell transplantation (SCT) is an exclusion only if the subject has active graft vs host disease or requires immunosuppression other than a constant stable dose of glucocorticoids (the latter is permitted)
High risk prediction score as determined by the Mount Sinai Acute Graft Versus Host Disease (GVHD) International Consortium (MAGIC) algorithm at either day  or day  post hematopoietic stem cell transplantation (HCT).
In subjects with prior hematopoietic progenitor cell transplantation, evidence of ongoing graft-versus-host disease (GVHD).
Has undergone prior allogeneic hematopoietic stem cell transplantation within the last  years. (Subjects who have had a transplant greater than  years ago are eligible as long as there are no symptoms of graft versus host disease (GVHD).
AML relapse >  months since autologous or allogeneic stem cell transplantation, provided there is no active graft-versus-host disease (GVHD) > grade ; no treatment with high dose steroids for GVHD (up to  mg prednisolone or equivalent); no treatment with immunosuppressive drugs with the exception of low dose cyclosporine and tacrolimus (blood levels of .-. ug/mL)
Patients with prior autologous or allogeneic hematopoietic cell transplantation (HCT) are eligible if relapse occurs provided symptoms of graft-versus host disease are well controlled with stable use of immunosuppressive agents
Patients who have had prior SCT are eligible if they have a relapse >  months since autologous or allogeneic stem cell transplantation provided, ) no clinically significant active graft-versus-host disease (GVHD > grade ); ) no treatment with high dose steroids for GVHD (i.e. >  mg prednisolone or equivalent per day); ) no treatment with immunosuppressive drugs with the exception of cyclosporine and tacrolimus
Chronic graft-versus-host disease requiring systemic immunosuppression post-allogeneic hematopoietic stem cell transplantation
Patients who have undergone stem cell transplantation (SCT), autologous or allogeneic, are eligible provided that they are >  days from stem cell infusion, have graft-versus-host disease (GVHD) =< grade  and are off immunosuppressive agents for >  days at time of registration
Patient must meet one of the following criteria: \r\n* Patient refractory to one or two standard induction regimen \r\n* Patients with a first untreated relapse within  years of documentation of clinical remission; patients relapsing after allogeneic stem cell transplantation are eligible if more than  months after transplantation and without sign of active graft versus host disease (GVHD)
Patients with prior autologous and allogeneic hematopoietic stem cell transplantation are eligible if patients are off immunosuppression for greater than  days and have no evidence of active graft versus host disease (GVHD) except grade  skin GVHD
Prior allogeneic transplants is allowed prior to study start (st dose of study medication), but patients must also be at least  months from date of stem cell infusion, have no evidence of graft versus host disease (GVHD), be off all immunosuppressant medications, and have recovered to =< grade  toxicities related to this procedure
Relapse >  months since autologous or allogeneic stem cell transplantation provided:\r\n* No active graft-versus-host disease (GVHD > grade )\r\n* No treatment with high dose steroids for GVHD (up to >=  mg prednisolone or equivalent per day)\r\n* No treatment with immunosuppressive drugs with the exception of low dose cyclosporine and tacrolimus
Patients with relapsed or primary refractory AML; patients with relapsed AML after allogeneic stem cell transplantation, including those who have received donor lymphocyte infusions, are eligible if they have no active graft versus host disease (GVHD) and are off immunosuppression
Previous allogeneic stem cell transplantation with active graft versus host disease (GVHD), or treatment with immunosuppressive therapy (excluding corticosteroids) in the  months prior to study entry
Has undergone prior allogeneic hematopoetic stem cell transplantation within the last  years. (Participants who have had a transplant greater than  years ago are eligible as long as there are no symptoms of Graft versus Host Disease [GVHD]).
Prior hematopoietic stem cell transplantation within  weeks of the first dose of study treatment or ongoing immunosuppressive therapy for graft versus host disease
Patients who have received allogeneic hematopoietic stem cell transplantation will be eligible  months after the procedure provided there is no evidence of active graft-versus-host disease and immunosuppressive treatment has been discontinued for at least  days.
Patients with allogeneic stem cell transplantation within the last  months or patients with active graft-versus-host disease (GVHD) will be excluded
For patients with relapsed/refractory disease: patients with prior autologous or allogeneic hematopoietic cell transplantation (HCT) for MDS/AML are eligible if relapse occurs provided symptoms of graft-versus host disease are well controlled with stable use of immunosuppressive agents
Active graft versus host disease (GVHD) after allogeneic stem cell transplantation; at least  months must have elapsed since completion of an allogeneic stem cell transplantation
Patients who have undergone stem cell transplantation (SCT), autologous or allogeneic, are eligible provided that they are >  days from stem cell infusion, have no active graft-versus-host disease (GVHD), are off immunosuppressive agents for >  days
Recipients of prior allogeneic hematopoietic stem cell transplantation for AML or acute leukemia of ambiguous lineage are eligible if they do not have graft-versus-host disease (GVHD) or they have quiescent GVHD whether or not they are receiving immunosuppressive therapy
Patients who have undergone prior stem cell transplantation will not be excluded from study entry; at least  months must have elapsed since autologous or allogeneic stem cell transplantation; patients must have no evidence of active graft versus host disease
Patients who have undergone an allogeneic hematopoietic cell transplantation (HSCT) within the last  years (yrs) are eligible for enrollment if they have no signs or symptoms of active graft versus host disease (GvHD) and are off all immune suppressive medications
Patients with prior autologous and allogeneic hematopoietic stem cell transplantation are eligible if patients are off immunosuppression for >  month and have no evidence of active graft versus host disease (GVHD) except grade  skin GVHD
Patients following allogeneic stem cell transplantation are eligible in the absence of graft versus host disease and are off immunosuppression for at least  days
Allogeneic stem cell transplantation within the last  days before first treatment with graft versus host disease requiring more than  mg of steroids per day. Steroid dosage must be stable within two weeks prior to start of treatment.
AML relapse >  months since autologous or allogeneic stem cell transplantation, provided they are in first or second relapse and: No active graft-versus-host disease (GVHD > grade ). No treatment with high dose steroids for GVHD (up to  mg Prednisolone or equivalent, Appendix G). No treatment with immunosuppressive drugs with the exception of low dose cyclosporine and tacrolimus (blood levels of .-. g/mL).
Patients with prior autologous or allogeneic hematopoietic cell transplantation (HCT) are eligible if relapse occurs provided symptoms of graft-versus host disease are well controlled with stable use of immunosuppressive agents
Patients with active graft versus host disease after allogeneic stem cell transplantation. At least  months must have elapsed since completion of allogeneic stem cell transplantation except for patients with AML, where at least  months must have elapsed;
Adult HCT survivors as defined by being at least  days post autologous or allogeneic transplantation for a malignant disease; all hematologic malignancies will be included; there is no restriction to enrollment by donor type, donor cell source, presence or absence of graft versus host disease
Prior allogeneic hematopoietic cell transplantation (HCT) with active graft versus host disease (GVHD) on therapeutic dosing of immunosuppression or prednisone >  mg daily equivalent
Patients with a history of allogeneic hematopoietic stem cell transplantation (HSCT) will be eligible if they are more than  days removed from the date of stem cell infusion, have no evidence of acute graft-versus-host disease (GVHD) or active chronic (grade -) GVHD, and are off of all transplant-related immunosuppression for at least  weeks
Has undergone prior allogeneic hematopoietic stem cell transplantation within the last  years. Note: Participants who have had a transplant greater than  years ago are eligible as long as there are no symptoms of graft-versus-host disease (GVHD).
